Lonza (LONN.SW) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $48.28B | Exchange | SIX |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | CH | CEO | Wolfgang Wienand |
| IPO Date | 1999-11-01 | CAGR | 5.36% |
| Employees | 20,141 | Website | www.lonza.com |
| Div. Yield | 0.5% | Payout Ratio | -339% |
| Buy Back Yield | 1.29% | Total Yield | 1.79% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $52.60B | P/E | 35.32 | Forward P/E | 25.59 | PEG | 0.94 |
| P/S | 10.93 | P/B | 8.51 | P/CF | 47.9 | P/FCF | 424.21 |
| Sales | $16.44B | Sales 1Y | 3.13% | Sales 3Y | 14.33% | Sales 5Y | 130.54% |
| EPS | $19.57 | EPS 1Y | -62.7% | EPS 3Y | -57.06% | EPS 5Y | -19.74% |
| Sales QoQ | 14.18% | EPS QoQ | -184.5% | Sales QoQ Avg | 3.38% | EPS QoQ Avg | -103.21% |
| Gross Margin | 35.79% | Operating Margin | 23.02% | Profit Margin | -1.74% | ROCE | 10.34% |
| ROA | -1% | ROE | -1% | Altman Z Score | 4.36 | Piotroski Score | 7 |
| Current Ratio | 1.66 | Quick Ratio | 1.21 | Cash Ratio | 0.12 | Op. CF Ratio | 0.16 |
| Debt/Equity | 0.51 | Debt/Assets | 0.23 | Lt Debt/Equity | 0.42 | Lt Debt/Cap. | 0.29 |
| Intrst Cov. | 10.33 | Inventory Turnover | 2.16 | Asset Turnover | 0.35 | Receivables Turnover | 3.3 |
| Enterprise Value | $52.60B | P/E Ratio | 35.32 |
| Forward P/E | 25.59 | PEG Ratio | 0.94 |
| P/S Ratio | 10.93 | P/B Ratio | 8.51 |
| P/CF Ratio | 47.9 | P/FCF Ratio | 424.21 |
| EPS | $19.57 | EPS Growth 1Y | -62.7% |
| EPS Growth 3Y | -57.06% | EPS Growth 5Y | -19.74% |
| Revenue Growth 1Y | 3.13% | Gross Margin | 0.36% |
| Operating Margin | 0.23% | Profit Margin | -0.02% |
| ROE | -0.01% | ROA | -0.01% |
| ROCE | 0.1% | Current Ratio | 1.66 |
| Quick Ratio | 1.21 | Cash Ratio | 0.12 |
| Debt/Equity | 0.51 | Interest Coverage | 10.33 |
| Altman Z Score | 4.36 | Piotroski Score | 7 |
Lonza (LONN.SW) valuation & financials
Lonza (LONN.SW) has a market capitalization of 48.28B CHF and trades at a price-to-earnings ratio of 35.3. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Lonza's revenue grew +3.1% over the last year.
Lonza's next earnings report is scheduled for July 22, 2026; analysts estimate EPS of 10.66 CHF. Check the earnings calendar to see all companies reporting this week.
Lonza (LONN.SW) — frequently asked questions
When does Lonza (LONN.SW) report earnings next?
Lonza is expected to report earnings on July 22, 2026. Analysts estimate EPS of 10.66 CHF.
What is Lonza's market cap?
Lonza (LONN.SW) has a market capitalization of 48.28B CHF.
What is LONN.SW's P/E ratio?
Lonza trades at a price-to-earnings ratio of 35.3, with trailing twelve-month EPS of 19.57 CHF.
How fast is Lonza growing?
Lonza's revenue grew +3.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)